Search
Cancer Clinical Trials in Durham, NC
A listing of 146 Cancer clinical trials in Durham, NC actively recruiting volunteers for paid trials and research studies in various therapeutic areas.
133 - 144 of 146
The city of Durham, North Carolina, currently has 146 active clinical trials seeking participants for Cancer research studies.
Featured Trial
Lung or Breast Cancer Treatment
Recruiting
Diagnosed w/ Lung or Breast Cancer - Underwent Cancer Treatment, Take a step towards hope and healing. Enroll now in our clinical trial for an innovative breast and lung cancer treatment
Conditions:
Cancer
Featured Trial
Paid Clinical Studies Nationwide
Recruiting
Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.
Featured Trial
Healthy Volunteer Trials
Recruiting
Healthy trials near you are looking for participants to help push medical research forward. Click through to learn more!
Conditions:
Healthy
Featured Trial
Non-Small Cell Lung Cancer Treatment
Recruiting
A Trial to Evaluate DZD9008 as a Treatment for People with Non-Small Cell Lung Cancer with EGFR Gene Mutations
Conditions:
NSCLC
Lung Cancer
Non-Small Cell Lung Cancer
Carcinoma
Non-Small-Cell Lung
Featured Trial
Breast Cancer Study
Recruiting
If you have stage 4 breast cancer, you may be able to help advance medical research. Learn about DYNASTY-Breast02 Study enrolling now.
Featured Trial
RSV Vaccine For Adults With Kidney, Liver or Lung Transplant
Recruiting
The RSVoice Trial is a Phase 3 clinical trial conducted by Moderna to evaluate the safety and immune response of an investigational vaccine aimed at preventing respiratory syncytial virus (RSV) infection in adults who have received a kidney, liver, or lung transplant.
Conditions:
Kidney Transplantation
Kidney Transplant
Liver Transplantation
Lung Transplantation
Chronic Kidney Disease
High Dose Testosterone for ATM, CDK12 or CHEK2 Altered Prostate Cancers
Recruiting
This study will determine whether the presence of DNA repair deficiency in the form of alterations in the genes ATM, CDK12 or CHEK2 predicts for a high likelihood of responding to the use of intermittent high dose testosterone. This therapy may result in responses in tumors which are genetically unstable because of DNA repair deficiency and this is a prospective study to test that hypothesis
Gender:
Male
Ages:
18 years and above
Trial Updated:
08/16/2023
Locations: Durham VA Medical Center, Durham, NC, Durham, North Carolina
Conditions: Metastatic Prostate Cancer
Real World Treatment Experience of Patients With Breast, Lung, Ovarian, Multiple Myeloma, or Acute Myelogenous Leukemia Using Remote Symptom Monitoring
Recruiting
The goal of this study is to create a data set to add to Carevive's registry from real world clinical and patient reported data collected using an electronic care planning system (CPS) with remote symptom monitoring that is used in routine care for cancer patients on active treatment.
Patients will complete a baseline survey in person using a secured device or remotely using their own electronic device in a location of their choice. Weekly electronic patient reported outcome (PRO) surveys are c... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
08/08/2023
Locations: Duke, Durham, North Carolina
Conditions: Breast Cancer, Lung Cancer, Multiple Myeloma, Ovarian Cancer, Acute Myelogenous Leukemia
Study of RP1 Monotherapy and RP1 in Combination With Nivolumab
Recruiting
RPL-001-16 is a Phase 1/2, open label, dose escalation and expansion clinical study of RP1 alone and in combination with nivolumab in adult subjects with advanced and/or refractory solid tumors, to determine the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D), as well as to evaluate preliminary efficacy.
Gender:
All
Ages:
18 years and above
Trial Updated:
08/01/2023
Locations: Duke Cancer Center, Durham, North Carolina
Conditions: Cancer, Melanoma (Skin), Mismatch Repair Deficiency, Microsatellite Instability, Non-melanoma Skin Cancer, Cutaneous Melanoma, NSCLC
Groningen International Study on Sentinel Nodes in Vulvar Cancer-III
Recruiting
Vulvar cancer patients with SN-metastasis > 2mm will receive chemoradiation instead of an inguinofemoral lymphadenectomy.
Gender:
Female
Ages:
18 years and above
Trial Updated:
07/27/2023
Locations: Duke University Medical Center, Durham, North Carolina
Conditions: Vulvar Cancer, Sentinel Lymph Node, Lymph Node Metastases
A Phase 1 Trial of ZN-A-1041 Enteric Capsules or Combination in Patients With HER2-Positive Advanced Solid Tumors
Recruiting
This will be a Phase 1, multicenter, open-label trial to evaluate the safety, tolerability, PK and efficacy of ZN-A-1041 as a monotherapy or in combination in patients with HER2-positive advanced solid tumors with or without brain metastases.
The study will consist of three phases: Phase 1a (dose escalation with ZN-A-1041 monotherapy), Phase 1b (dose escalation with ZN-A-1041 combination therapy) and Phase 1c (dose expansion with ZN-A-1041 combination therapy).
Gender:
All
Ages:
18 years and above
Trial Updated:
07/26/2023
Locations: Duke Cancer Institute, Durham, North Carolina
Conditions: Advanced Solid Tumors, HER2-positive Breast Cancer
Phase Ib/II Trial of Abemaciclib and Elacestrant in Patients With Brain Metastasis Due to HR+/Her2- Breast Cancer
Recruiting
This is a multi-institutional, single arm, open label, Phase Ib/II study of abemaciclib in combination with elacestrant in patients with HR+/Her2- breast cancer metastatic to the brain. Patients may have received up to two prior lines of systemic chemotherapy for locally advanced or metastatic disease. There will be no limit on prior use of endocrine therapy including aromatase inhibitors, tamoxifen and fulvestrant, given a documented clinical benefit of elacestrant in this setting.
Gender:
All
Ages:
18 years and above
Trial Updated:
07/25/2023
Locations: Duke Cancer Center, Durham, North Carolina
Conditions: Breast Cancer
Comparison of Chemotherapy Before and After Surgery Versus After Surgery Alone for the Treatment of Gallbladder Cancer
Recruiting
This phase II/III trial compares the effect of adding chemotherapy before and after surgery versus after surgery alone (usual treatment) in treating patients with stage II-III gallbladder cancer. Chemotherapy drugs, such as gemcitabine and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving chemotherapy before surgery may make the tumor smaller; therefore, may reduce the exten... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
06/21/2023
Locations: Duke University Medical Center, Durham, North Carolina
Conditions: Stage II Gallbladder Cancer AJCC v8, Stage IIA Gallbladder Cancer AJCC v8, Stage IIB Gallbladder Cancer AJCC v8, Stage III Gallbladder Cancer AJCC v8, Stage IIIA Gallbladder Cancer AJCC v8, Stage IIIB Gallbladder Cancer AJCC v8
Crizotinib in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Removed by Surgery and ALK Fusion Mutations (An ALCHEMIST Treatment Trial)
Recruiting
This randomized phase III trial studies how well crizotinib works in treating patients with stage IB-IIIA non-small cell lung cancer that has been removed by surgery and has a mutation in a protein called anaplastic lymphoma kinase (ALK). Mutations, or changes, in ALK can make it very active and important for tumor cell growth and progression. Crizotinib may stop the growth of tumor cells by blocking the ALK protein from working. Crizotinib may be an effective treatment for patients with non-sma... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
06/20/2023
Locations: Duke University Medical Center, Durham, North Carolina
Conditions: ALK Gene Rearrangement, ALK Gene Translocation, ALK Positive, Stage IB Non-Small Cell Lung Carcinoma AJCC v7, Stage II Non-Small Cell Lung Cancer AJCC v7, Stage IIA Non-Small Cell Lung Carcinoma AJCC v7, Stage IIB Non-Small Cell Lung Carcinoma AJCC v7, Stage IIIA Non-Small Cell Lung Cancer AJCC v7
A Randomized Pilot Study of Evolocumab Plus Nivolumab/Ipilimumab in Treatment-Naïve Patients With Metastatic NSCLC
Recruiting
This is a research study to find out the safety and tolerability of combining the drug evolucumab with standard immunotherapy in people with advanced lung cancer (a type called non-small cell lung cancer).
Nivolumab (Opdivo™) and ipilimumab (Yervoy™) are immunotherapy-type drugs which are approved for the treatment of advanced lung cancer that has expression of PD-L1 greater than or equal to 1%. Evolucumab is being combined with nivolumab and ipilimumab to see if it will improve the anti-tumor... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
05/08/2023
Locations: Duke Univ. Medical Center, Durham, North Carolina
Conditions: Lung Cancer Metastatic
International Registry for Men With Advanced Prostate Cancer (IRONMAN)
Recruiting
Our intent is to establish the International Registry to Improve Outcomes in Men with Advanced Prostate Cancer (IRONMAN) as a prospective, international cohort of minimum 5,000 men with advanced cancer, including men with mHSPC and M0/M1 CRPC. The goal is to establish a population-based registry and recruit patients across academic and community practices from Australia, Barbados, Brazil, Canada, Ireland, Jamaica, Kenya, Nigeria, Norway, Spain, South Africa, Sweden, Switzerland, the United Kingd... Read More
Gender:
Male
Ages:
21 years and above
Trial Updated:
05/04/2023
Locations: Durham VA Medical Center, Durham, North Carolina +2 locations
Conditions: Prostate Cancer
KM3D Multicenter Cancer Consortium: Predicting Patient Response Using 3D Cell Culture Models
Recruiting
This study will assess the ability of the Known Medicine platform to predict the efficacy of certain cancer drug treatments and to validate that tumor organoid drug sensitivity is representative of patient treatment outcomes.
Gender:
All
Ages:
18 years and above
Trial Updated:
04/21/2023
Locations: Duke Cancer Institute, Durham, North Carolina
Conditions: Cancer, Predictive Cancer Model, Effects of Chemotherapy
Screening for High Frequency Malignant Disease
Recruiting
The SHIELD (Screening for High Frequency Malignant Disease) study is a prospective, observational, multi-site basket design trial without randomization. The primary objective of the study is to evaluate the sensitivity and specificity of a blood-based GuardantLUNAR-2 test to detect high frequency cancer in screen-relevant populations.
Gender:
All
Ages:
Between 50 years and 80 years
Trial Updated:
04/10/2023
Locations: Durham VA Medical Center, Durham, North Carolina
Conditions: Lung Cancer
133 - 144 of 146